Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - Still a Buy?

Key Points

• Pharming Group's stock saw a trading volume increase of 28% with 7,617 shares exchanged, despite the stock price dropping 8.5% to $11.16.
• The company's latest earnings report showed an EPS of $0.06, exceeding analysts' expectations, with revenue reaching $93.20 million compared to an expected $70.36 million.
• Institutional investor Silverberg Bernstein Capital Management raised its stake in Pharming Group by 8.6%, now holding approximately 0.08% of the company's stock worth $557,000.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) saw an uptick in trading volume on Tuesday . 7,617 shares traded hands during mid-day trading, an increase of 28% from the previous session's volume of 5,934 shares.The stock last traded at $11.16 and had previously closed at $12.10.

Pharming Group Trading Up 1.2%

The firm has a market cap of $779.64 million, a PE ratio of -87.54 and a beta of 0.02. The company has a current ratio of 2.79, a quick ratio of 2.07 and a debt-to-equity ratio of 0.38. The business has a fifty day moving average price of $10.88 and a 200 day moving average price of $9.63.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.06 EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.16. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%. The business had revenue of $93.20 million for the quarter, compared to the consensus estimate of $70.36 million. Analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC bought a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 2,979 shares of the company's stock, valued at approximately $32,000. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.